Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2016 2
2019 2
2020 5
2021 2
2022 3
2023 1
2024 2
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
[Treatment of non-small cell lung cancer].
Hopstaken JS, de Ruiter JC, van Diessen JNA, Theelen WSME, Monkhorst K, Hartemink KJ. Hopstaken JS, et al. Among authors: van diessen jna. Ned Tijdschr Geneeskd. 2021 Feb 4;165:D5486. Ned Tijdschr Geneeskd. 2021. PMID: 33651512 Review. Dutch.
In response to Park, et al.
van Diessen JNA, Kwint MH, Sonke JJ, Belderbos JSA. van Diessen JNA, et al. Radiother Oncol. 2020 Jun;147:245-246. doi: 10.1016/j.radonc.2020.03.036. Epub 2020 Apr 4. Radiother Oncol. 2020. PMID: 32312603 No abstract available.
Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non-Small Cell Lung Cancer: The Induction Trial.
Smeenk MM, van Diessen JNA, Boellaard TN, Hartemink KJ, de Vries JF, van der Noort V, Badrising SK, Owers EC, Monkhorst K, van den Heuvel MM, Theelen WSME. Smeenk MM, et al. Among authors: van diessen jna. Clin Cancer Res. 2025 Mar 17;31(6):1037-1046. doi: 10.1158/1078-0432.CCR-24-3476. Clin Cancer Res. 2025. PMID: 39821070 Free PMC article. Clinical Trial.
Patient-reported outcomes after personalised dose-escalation for stage II-III non-small-cell lung cancer patients: Results from the randomised ARTFORCE PET-Boost trial.
Cooke SA, Belderbos JSA, Reymen B, Lambrecht M, Fredberg Persson G, Faivre-Finn C, Dieleman EMT, van Diessen JNA, Sonke JJ, de Ruysscher D. Cooke SA, et al. Among authors: van diessen jna. Radiother Oncol. 2024 Jul;196:110312. doi: 10.1016/j.radonc.2024.110312. Epub 2024 Apr 24. Radiother Oncol. 2024. PMID: 38663582 Clinical Trial.
18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial.
Cooke SA, de Ruysscher D, Reymen B, Lambrecht M, Fredberg Persson G, Faivre-Finn C, Dieleman EMT, Lewensohn R, van Diessen JNA, Sikorska K, Lalezari F, Vogel W, van Elmpt W, Damen EMF, Sonke JJ, Belderbos JSA. Cooke SA, et al. Among authors: van diessen jna. Radiother Oncol. 2023 Apr;181:109492. doi: 10.1016/j.radonc.2023.109492. Epub 2023 Jan 24. Radiother Oncol. 2023. PMID: 36706958 Clinical Trial.
Importance of tumour volume and histology in trimodality treatment of patients with Stage IIIA non-small cell lung cancer-results from a retrospective analysis.
Joosten PJM, Dickhoff C, van der Noort V, Smeekens M, Numan RC, Klomp HM, van Diessen JNA, Belderbos JSA, Smit EF, Monkhorst K, Oosterhuis JWA, van den Heuvel MM, Dahele M, Hartemink KJ. Joosten PJM, et al. Among authors: van diessen jna. Interact Cardiovasc Thorac Surg. 2022 Mar 31;34(4):566-575. doi: 10.1093/icvts/ivab291. Interact Cardiovasc Thorac Surg. 2022. PMID: 34734237 Free PMC article.
19 results